about
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialBivalirudin during primary PCI in acute myocardial infarctionPredictors and Long-Term Clinical Impact of Acute Stent Malapposition: An Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Intravascular Ultrasound Substudy.Impact of multiple complex plaques on short- and long-term clinical outcomes in patients presenting with ST-segment elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIComparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial).Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials.The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.Percutaneous Coronary Intervention of Saphenous Vein Graft.Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy.Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).Prevalence, Features, and Prognostic Importance of Edge Dissection After Drug-Eluting Stent Implantation: An ADAPT-DES Intravascular Ultrasound Substudy.Etiology, Frequency, and Clinical Outcomes of Myocardial Infarction After Successful Drug-Eluting Stent Implantation: Two-Year Follow-Up From the ADAPT-DES Study.Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITIProton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study.Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES.Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry.Cerebrovascular events after a primary percutaneous coronary intervention strategy for acute ST-segment-elevation myocardial infarction: analysis from the HORIZONS-AMI Trial.Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents.Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial.Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: one-year results from the INFUSE-AMI trial.Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial.Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.Long-term follow-up of attenuated plaques in patients with acute myocardial infarction: an intravascular ultrasound substudy of the HORIZONS-AMI trial.Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy.Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with RevascularizaIncidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry.Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry).Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes.
P50
Q28256871-64279DA2-7B7C-41D7-AFF9-D1E368EFB1EDQ28281179-8B2B47BC-760A-46A3-8693-B1DAF2838333Q30366121-306FBBAA-4D64-45E4-B94E-B082F476E570Q30398247-AB4DAD95-BE3A-4ADA-AD04-52F2073CF7C0Q33413571-E67EED2C-2BE5-4F77-ABB8-E48E3A7FD837Q33419676-030D0BC5-1438-48CA-B6B8-0AEC544EC668Q34486268-2754B936-1239-4ADA-A20D-33B68C4A5D30Q37599599-FABAB1F8-F35B-4806-8DE9-057390CD5C41Q38376910-6A680423-7B90-44A9-B233-F1E9ED1DC7B4Q38378126-0816C516-CD66-42EA-A270-5282A23F9352Q38379501-C6133D28-E1D5-4192-B3B9-0BF7FB2320D7Q38380899-4407E12F-1E6F-4734-9897-E768169E141EQ38390273-406F525F-FAAF-45B3-A6D4-047908E25179Q38398711-BE49742A-D97D-4955-95E4-0CD368FA875EQ38400512-32610412-227B-46CD-A930-F9BA2FB5A7F2Q38402115-55DF8746-6734-44E7-9595-DCC3BCAA10FFQ38402937-242066AE-817D-47E4-98C3-74C82C64EDD1Q38410176-2E3B1386-DC3B-4B44-A601-000C432D25AAQ38413579-C7F0D172-CF3D-44B5-B5F6-A5873245C820Q38417020-55D1D37F-B978-4CC4-AF8A-A43CD89C90BBQ38418337-B583E1C5-927D-460B-AAA6-99AA0F394BECQ38428199-78DEBB7E-15A1-4AC2-9F79-1EC62F941996Q38440568-F4BDEB3E-4E4F-49E6-951E-601C318BFD54Q38443687-3CEB3597-178C-4A1E-B919-3E77B976EB92Q38453848-D8F95620-5936-4AC9-A00A-19446E755EE9Q38454235-A566BA25-1EDF-4767-9D1A-044F8CDF4E70Q38460595-5E355582-9FBC-466F-92BD-58193AC17562Q38474127-23E69FE5-3430-4B96-878A-EAB04EEA787EQ38474268-0DDC414F-5010-420B-9216-76361FF16FBEQ38490870-6817E8AF-3D7E-4543-8648-EB5098DD26BFQ38493997-8D38E554-FFB3-49EA-88C9-FF2309747E51Q38500556-519720C0-9276-411E-B60D-8090F037EBB1Q38885545-7433356A-9A4D-40CA-A963-51020232CF8AQ38886576-DF31F374-5C1C-4EA9-BE60-8C8C1AC6836EQ38886583-F10C538F-CAD3-4BAD-BE0E-E3D75B339CFFQ38890443-CDFAE3AB-5EDB-4595-BF90-EA8E7246C1F7Q38938312-B02ECD4E-5307-4C53-94FF-D02420E6D2E9Q38938320-1C7E47A5-C45E-45B2-AC3A-C7D650E13667Q39438758-959CF813-544A-4FCD-8478-B97543467ED5Q39438763-D28E26E5-81C5-42FA-8EBA-9D7D6914236D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bernhard Witzenbichler
@ast
Bernhard Witzenbichler
@en
Bernhard Witzenbichler
@es
Bernhard Witzenbichler
@nl
Bernhard Witzenbichler
@sl
type
label
Bernhard Witzenbichler
@ast
Bernhard Witzenbichler
@en
Bernhard Witzenbichler
@es
Bernhard Witzenbichler
@nl
Bernhard Witzenbichler
@sl
prefLabel
Bernhard Witzenbichler
@ast
Bernhard Witzenbichler
@en
Bernhard Witzenbichler
@es
Bernhard Witzenbichler
@nl
Bernhard Witzenbichler
@sl
P106
P21
P31
P496
0000-0001-9322-1926